Table 1.
Patient characteristics
| Early RA | HC | ||||
|---|---|---|---|---|---|
| (n = 152) | (n = 88) | ||||
| Time after treatment initiation (months) | 0 | 6 | 12 | 24 | |
| Age (years) | 56 (43–63) | – | – | – | 53 (46–61) |
| Gender (% female) | 69 | – | – | – | 68 |
| Baseline characteristics | |||||
| Disease duration (days) | 84 (43–130) | – | – | – | – |
| IgM-RF (% positive) | 71 | – | – | – | – |
| Anti-CCP antibody (% positive) | 65 | – | – | – | – |
| Treated with adalimumab (%) | 50 | – | – | – | – |
| Disease activity | |||||
| HAQ (0–3) | 1.1 (0.8–1.8) | 0.1 (0–0.6) | 0.1 (0–0.5) | 0.1 (0–0.5) | – |
| DAS28CRP (0–10) | 5.6 (4.9–6.3) | 2.4 (1.8–3.0) | 2.0 (1.8–2.8) | 2.0 (1.8–2.7) | – |
| Radiographic progression | |||||
| Total Sharp score (% progressors) | – | 32 | 41 | 48 | – |
Data are expressed as the median with interquartile range unless otherwise indicated. CCP Cyclic citrullinated peptide, DAS28CRP disease activity score 28 based on C-reactive protein, HC healthy control, IgM immunoglobulin M, RF rheumatoid factor, HAQ health assessment questionnaire, RA rheumatoid arthritis